Cardiovascular and Metabolic Efficacy of GLP-1RAs: A Pooled Analysis of 15 Trials

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  European Journal of Heart Failure  https://doi.org/10.1002/ejhf.70048 
Dr. Tariq Jamal Siddiqi  et al.

Points

Researchers analyzed fifteen clinical trials involving over eighty-seven thousand participants to assess the cardiovascular impact of GLP-1 receptor agonists across multiple metabolic conditions.
The study determined that these agents significantly reduced the relative risk of composite heart failure hospitalization or cardiovascular death in patients with diabetes and obesity.
GLP-1 receptor agonists demonstrated a hazard ratio of 0.88 for cardiovascular death in heart failure patients and remained safe regarding serious adverse events.
Data indicated a divergence in patients with heart failure with reduced ejection fraction who showed reduced mortality but a non-significant increase in hospitalization risk.
The findings support the broad use of these therapies for overlapping cardiovascular-kidney-metabolic diseases while highlighting the need for specific trials regarding reduced ejection fraction.

Summary

This study assessed the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in reducing heart failure hospitalization (HFH) and cardiovascular (CV) death across patients with overlapping cardiovascular-kidney-metabolic (CKM) comorbidities. Pooled data from 15 clinical trials involving 87,549 participants were analyzed using random-effects models. The primary outcome was a composite of HFH or CV death, while secondary outcomes analyzed these events individually across subgroups including type 2 diabetes mellitus (T2DM), heart failure (HF), obesity, and chronic kidney disease (CKD).

Compared with placebo, GLP-1RA therapy significantly reduced the relative risk of the composite primary outcome in patients with heart failure (HR 0.81, 95% CI 0.69–0.96), T2DM (HR 0.85, 95% CI 0.78–0.93), and obesity (HR 0.70, 95% CI 0.58–0.86). A non-significant reduction was observed in the CKD cohort (HR 0.79, 95% CI 0.61–1.01). Regarding CV death specifically, significant reductions were found in patients with HF (HR 0.88, 95% CI 0.77–0.99), T2DM (HR 0.85, 95% CI 0.78–0.93), and obesity (HR 0.83, 95% CI 0.73–0.93), confirming broad cardioprotective benefits across most CKM phenotypes.

While benefits were generally consistent, the analysis identified a divergence in patients with heart failure with reduced ejection fraction (HFrEF). In this subgroup, GLP-1RAs were associated with a non-significant numeric increase in HFH (HR 1.17, 95% CI 0.93–1.47), despite significantly reducing the risk of CV death (HR 0.67, 95% CI 0.50–0.90). Overall, GLP-1RAs were not associated with an increased risk of serious adverse events (RR 0.94, 95% CI 0.89–1.00). The authors suggest definitive outcome trials are required to clarify the therapeutic role of these agents specifically within the HFrEF population.

Link to the article: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70048

References

Siddiqi, T. J., Khan, M. S., Waqas, S. A., Van Spall, H. G. C., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., & Greene, S. J. (2025). Effect of glucagon‐like peptide‐1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular‐kidney‐metabolic comorbidity. European Journal of Heart Failure, ejhf.70048. https://doi.org/10.1002/ejhf.70048